ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	16.49B +21.9%
Revenue (ttm)	3.14B -2.3%
Net Income	107.46M -56.2%
EPS	0.13 -58.1%
Shares Out	790.74M
PE Ratio	160.38
Forward PE	n/a
Dividend	0.29 (1.46%)
Ex-Dividend Date	Jul 2, 2026

Volume	547,340
Open	20.85
Previous Close	20.85
Day's Range	20.35 - 21.05
52-Week Range	16.40 - 29.10
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 16, 2026

Data Sources Report a data error